Prevalence and Clinical Significance of Concurrent CBD Stones in Acute Biliary Pancreatitis
Epidemiological Data and Clinical Context
- The American Gastroenterological Association estimates that gallstones are the causal factor in up to 50% of all acute pancreatitis cases, making CBD stone evaluation critical in this population 1, 2
- In contrast to the general gallstone population, where CBD stones occur in only 10-20% of cases, and acute cholecystitis, where the incidence is even lower at 5-15%, the substantially higher prevalence in pancreatitis reflects the pathophysiologic mechanism—stones migrating through the CBD and causing pancreatic duct obstruction 3, 4, 5
Management Implications
- The American College of Gastroenterology suggests that given the high prevalence and significant morbidity risk, patients with acute biliary pancreatitis warrant systematic evaluation for CBD stones, with the decision for ERCP guided by clinical factors and bilirubin levels 2, 5